TY - JOUR
T1 - Familial hypercholesterolaemia: cholesterol efflux and coronary disease
AU - Versmissen, Jorie
AU - Vongpromek, Ranitha
AU - Yahya, Reyhana
AU - van der Net, Jeroen B.
AU - van Vark-van der Zee, Leonie
AU - Blommesteijn-Touw, Jeannette
AU - Wattimena, J. L. Darcos
AU - Rietveld, Trinet
AU - Pullinger, Clive R.
AU - Christoffersen, Christina
AU - Dahlback, Bjorn
AU - Kane, John P.
AU - Mulder, Monique
AU - Sijbrands, Eric J. G.
PY - 2016/7
Y1 - 2016/7
N2 - Coronary heart disease (CHD) risk inversely associates with levels of high-density lipoprotein cholesterol (HDL-C). The protective effect of HDL is thought to depend on its functionality, such as its ability to induce cholesterol efflux.We compared plasma cholesterol efflux capacity between male familial hypercholesterolaemia (FH) patients with and without CHD relative to their non-FH brothers, and examined HDL constituents including sphingosine-1-phosphate (S1P) and its carrier apolipoprotein M (apoM).Seven FH patients were asymptomatic and six had experienced a cardiac event at a mean age of 39?years. Compared to their non-FH brothers, cholesterol efflux from macrophages to plasma from the FH patients without CHD was 16?22% (mean?SD) higher and to plasma from the FH patients with CHD was 7?8% lower (P?=?0?03, CHD vs. non-CHD). Compared to their non-FH brothers, FH patients without CHD displayed significantly higher levels of HDL-cholesterol, HDL-S1P and apoM, while FH patients with CHD displayed lower levels than their non-FH brothers.A higher plasma cholesterol efflux capacity and higher S1P and apoM content of HDL in asymptomatic FH patients may play a role in their apparent protection from premature CHD.? 2016 The Authors. European Journal of Clinical Investigation published by John Wiley & Sons Ltd on behalf of Stichting European Society for Clinical Investigation Journal Foundation.
AB - Coronary heart disease (CHD) risk inversely associates with levels of high-density lipoprotein cholesterol (HDL-C). The protective effect of HDL is thought to depend on its functionality, such as its ability to induce cholesterol efflux.We compared plasma cholesterol efflux capacity between male familial hypercholesterolaemia (FH) patients with and without CHD relative to their non-FH brothers, and examined HDL constituents including sphingosine-1-phosphate (S1P) and its carrier apolipoprotein M (apoM).Seven FH patients were asymptomatic and six had experienced a cardiac event at a mean age of 39?years. Compared to their non-FH brothers, cholesterol efflux from macrophages to plasma from the FH patients without CHD was 16?22% (mean?SD) higher and to plasma from the FH patients with CHD was 7?8% lower (P?=?0?03, CHD vs. non-CHD). Compared to their non-FH brothers, FH patients without CHD displayed significantly higher levels of HDL-cholesterol, HDL-S1P and apoM, while FH patients with CHD displayed lower levels than their non-FH brothers.A higher plasma cholesterol efflux capacity and higher S1P and apoM content of HDL in asymptomatic FH patients may play a role in their apparent protection from premature CHD.? 2016 The Authors. European Journal of Clinical Investigation published by John Wiley & Sons Ltd on behalf of Stichting European Society for Clinical Investigation Journal Foundation.
KW - Apolipoprotein M
KW - cholesterol efflux
KW - familial hypercholesterolaemia
KW - high-density lipoprotein
KW - sphingolipids
KW - sphingosine-phosphate
U2 - 10.1111/eci.12643
DO - 10.1111/eci.12643
M3 - Article
C2 - 27208892
SN - 0014-2972
VL - 46
SP - 643
EP - 650
JO - European Journal of Clinical Investigation
JF - European Journal of Clinical Investigation
IS - 7
ER -